Pfizer, Biontech seek Japan regulatory approval of COVID shot for young
children
Send a link to a friend
 [July 14, 2022]
TOKYO (Reuters) - Pfizer Inc and
BioNTech SE have sought approval from Japan's health ministry for use of
their COVID-19 vaccine for use in children aged six months to four
years, the companies said in a statement on Thursday.
The filing follows approval last month by U.S. regulators for Moderna
Inc's two-dose vaccine and the Pfizer-BioNTech three-shot regimen for
children in the same age group.
The majority of COVID vaccinations in Japan have used the Pfizer
vaccine, authorised by regulators for children aged five to 11 in
January.
[to top of second column]
|
A 4-year-old receives a coronavirus disease (COVID-19) vaccine for
children under five years old at Skippack Pharmacy in Schwenksville,
Pennsylvania, U.S., June 21, 2022. REUTERS/Hannah Beier
 (Reporting by Rocky Swift; Editing
by Clarence Fernandez)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
